<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514302</url>
  </required_header>
  <id_info>
    <org_study_id>TS202101</org_study_id>
    <nct_id>NCT04514302</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19</brief_title>
  <official_title>Phase I, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Antiviral Efficacy of Three Different Single Doses of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) in Adult Patients With Mild COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Jose Tec de Monterrey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inosan Biopharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital San Jose Tec de Monterrey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind phase I clinical study of&#xD;
      anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS) to evaluate the safety and&#xD;
      antiviral efficacy for the treatment of adult patients with mild COVID-19 and low risk of&#xD;
      disease progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 27, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Average change from baseline in viral load as quantified by RT-qPCR from nasopharyngeal swab samples</measure>
    <time_frame>Baseline to days 2, 4, 7, 14 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with undetectable viral load as quantified by RT-qPCR from nasopharyngeal swab samples</measure>
    <time_frame>At days 2, 4, 7, 14 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of viral activity</measure>
    <time_frame>Baseline to 28 days</time_frame>
    <description>Number of days in which viral load remains detectable as quantified by RT-qPCR from nasopharyngeal swab samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events presented early after infusion</measure>
    <time_frame>Baseline to 24 hrs</time_frame>
    <description>Number of adverse events per group presented in the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events presented later after infusion</measure>
    <time_frame>Day 2 until day 28</time_frame>
    <description>Number of adverse events per group presented 24 hours past infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-INOSARS antibodies</measure>
    <time_frame>Baseline and day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of a 150 mL saline solution administered intravenously as an infusion over 40 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INOSARS dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INOSARS dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 15 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INOSARS dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 30 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)</intervention_name>
    <description>INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.</description>
    <arm_group_label>INOSARS dose 1</arm_group_label>
    <arm_group_label>INOSARS dose 2</arm_group_label>
    <arm_group_label>INOSARS dose 3</arm_group_label>
    <other_name>INOSARS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria&#xD;
&#xD;
          -  Outpatient with a RT-qPCR confirmation of SARS-CoV-2 infection&#xD;
&#xD;
          -  Body Mass Index (BMI) at screening of 18.0 - 34.9 kg/m^2&#xD;
&#xD;
          -  Presence of at least one symptom consistent with COVID-19&#xD;
&#xD;
          -  Mild illness as defined by no requirement of supplementary oxygen or hospitalization&#xD;
             criteria are met&#xD;
&#xD;
        Key Exclusion criteria&#xD;
&#xD;
          -  Presence of a risk factor for disease progression documented for COVID-19 such as:&#xD;
             uncontrolled diabetes, uncontrolled hypertension, cardiovascular disease, pulmonary&#xD;
             disease, COPD, asthma, active cancer, immunosuppression, hypercoagulable states, CKD&#xD;
             currently under dialysis&#xD;
&#xD;
          -  Documented allergy to equine serum proteins&#xD;
&#xD;
          -  Previous hospitalization due to COVID-19&#xD;
&#xD;
          -  Supplementary oxygen, invasive ventilation, or mechanical circulatory support&#xD;
             requirements&#xD;
&#xD;
          -  Having received convalescent plasma or intravenous immunoglobulins for the treatment&#xD;
             of COVID-19&#xD;
&#xD;
          -  Previous vaccination or plans to get vaccinated for COVID-19&#xD;
&#xD;
          -  In the opinion of investigator, other health conditions that suppose an increased risk&#xD;
             of progression of disease&#xD;
&#xD;
        NOTE: Other inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José F Castilleja-Leal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellness and Prevention Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Servando Cardona-Huerta, MD, Ph. D.</last_name>
    <phone>+5218112121946</phone>
    <email>servandocardona@tec.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alejandro Torres-Quintanilla, MD, MSc</last_name>
    <phone>+528180205853</phone>
    <email>atorresq@tec.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital San José</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Servando Cardona-Huerta, MD, PhD</last_name>
      <phone>+5218112121946</phone>
      <email>servandocardona@tec.mx</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia de la Rosa-Pacheco, MD</last_name>
      <phone>+5218111832730</phone>
      <email>sylvia.delarosa@tec.mx</email>
    </contact_backup>
    <investigator>
      <last_name>José Fe Castilleja-Leal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.</citation>
    <PMID>32445440</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Jose Tec de Monterrey</investigator_affiliation>
    <investigator_full_name>Servando Cardona-Huerta</investigator_full_name>
    <investigator_title>Wellness and Prevention Director</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Immunoglobulin fragments</keyword>
  <keyword>Hyperimmune equine serum</keyword>
  <keyword>Passive immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

